#USA #Class Action #Philadelphia #Berger Montague #Spectrum Pharmaceuticals

Reminder for Spectrum Pharmaceuticals Investors

Attention Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) investors! A significant deadline is fast approaching as the national plaintiffs' law firm, Berger Montague PC, is in the process of investigating potential securities fraud claims against the company. This investigation targets investors who purchased or otherwise acquired shares of Spectrum during the specified class period from March 17, 2022, to September 22, 2022.

What’s at Risk?

The heart of this investigation revolves around allegations that Spectrum made misleading statements related to its Pinnacle Study, which is a clinical trial for poziotinib intended for lung cancer treatment. The firm asserts that these misrepresentations have impacted investors’ decisions, as many individuals could have been misled about the company’s financial standing and investment potential.

In light of these allegations, investors who bought stocks during the class period have until September 24, 2025 to seek appointment as lead plaintiff representative in the ongoing class action lawsuit. This is an essential step to ensure that your voice and rights as an investor are upheld.

What Should Investors Do?

Potential plaintiffs are strongly encouraged to review their rights and consult with legal professionals who can provide guidance on how to proceed. Those interested can reach out to the attorneys at Berger Montague, such as Andrew Abramowitz at (215) 875-3015, or Caitlin Adorni at (267) 764-4865, for further information on the class action and the necessary steps.

Impact of Recent Events

Additionally, it's noteworthy that Spectrum shares were delisted following their merger with Assertio Holdings, Inc. (NASDAQ: ASRT). This strategic merger raises questions about the future of Spectrum and its operational strategies going forward. For investors, this adds an extra layer of complexity to determining the viability of their investments in the company.

About Berger Montague

Founded in 1970, Berger Montague has built a strong reputation for advocating for investors in securities class action litigation. With offices situated in major cities across the United States, the firm's goal is to protect investors and ensure accountability for misleading corporate practices.

Conclusion

As the deadline approaches, it’s crucial for Spectrum Pharmaceuticals investors to be proactive. Being informed and taking necessary action can empower you to safeguard your financial interests. Stay updated on the developments surrounding this lawsuit and consult your legal professionals for personalized advice. Together, investors can strive for accountability and potential restitution from the parties responsible for any misleading information.